FNCH vs. TCON, PALI, FRTX, KRBP, XXII, GMDAQ, ALBT, CHRO, ELOX, and GMDA
Should you be buying Finch Therapeutics Group stock or one of its competitors? The main competitors of Finch Therapeutics Group include TRACON Pharmaceuticals (TCON), Palisade Bio (PALI), Fresh Tracks Therapeutics (FRTX), Kiromic BioPharma (KRBP), 22nd Century Group (XXII), Gamida Cell (GMDAQ), Avalon GloboCare (ALBT), Chromocell Therapeutics (CHRO), Eloxx Pharmaceuticals (ELOX), and Gamida Cell (GMDA).
Finch Therapeutics Group (NASDAQ:FNCH) and TRACON Pharmaceuticals (NASDAQ:TCON) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, dividends, institutional ownership, risk, community ranking, valuation, media sentiment, earnings and analyst recommendations.
TRACON Pharmaceuticals received 255 more outperform votes than Finch Therapeutics Group when rated by MarketBeat users. Likewise, 58.50% of users gave TRACON Pharmaceuticals an outperform vote while only 52.63% of users gave Finch Therapeutics Group an outperform vote.
In the previous week, Finch Therapeutics Group had 1 more articles in the media than TRACON Pharmaceuticals. MarketBeat recorded 1 mentions for Finch Therapeutics Group and 0 mentions for TRACON Pharmaceuticals. Finch Therapeutics Group's average media sentiment score of 0.67 beat TRACON Pharmaceuticals' score of 0.00 indicating that Finch Therapeutics Group is being referred to more favorably in the media.
TRACON Pharmaceuticals has higher revenue and earnings than Finch Therapeutics Group. TRACON Pharmaceuticals is trading at a lower price-to-earnings ratio than Finch Therapeutics Group, indicating that it is currently the more affordable of the two stocks.
TRACON Pharmaceuticals has a consensus target price of $60.00, suggesting a potential upside of 3,074.60%. Given TRACON Pharmaceuticals' higher possible upside, analysts clearly believe TRACON Pharmaceuticals is more favorable than Finch Therapeutics Group.
TRACON Pharmaceuticals' return on equity of -10.25% beat Finch Therapeutics Group's return on equity.
21.8% of Finch Therapeutics Group shares are held by institutional investors. Comparatively, 11.6% of TRACON Pharmaceuticals shares are held by institutional investors. 44.9% of Finch Therapeutics Group shares are held by insiders. Comparatively, 5.3% of TRACON Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Finch Therapeutics Group has a beta of 0.46, meaning that its share price is 54% less volatile than the S&P 500. Comparatively, TRACON Pharmaceuticals has a beta of 0.95, meaning that its share price is 5% less volatile than the S&P 500.
Summary
TRACON Pharmaceuticals beats Finch Therapeutics Group on 10 of the 16 factors compared between the two stocks.
Get Finch Therapeutics Group News Delivered to You Automatically
Sign up to receive the latest news and ratings for FNCH and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding FNCH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Finch Therapeutics Group Competitors List
Related Companies and Tools
